We publish, you pick: FiercePharma’s 10 best-read stories of 2014

Tracy Staton In pharma, here are the top 10 news stories of the year so far, based on web traffic. FiercePharma News

The most popular stories and special reports in FierceBiotech Research, FiercePharmaManufacturing, and the rest of our Life Sciences publications

Alok Saboo FierceBiotech News

Valeant CEO touts R&D output with new dermatology approval

Carly Helfand Less than two weeks after losing longtime acquisition target Allergan–which happily sold itself to Actavis to dodge Valeant's hostile bid and the R&D cuts ...

FDA slaps down Bristol-Myers’ marketing pitch for hep C drug daclatasvir

John Carroll The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail ...

Ampio calls off a $30M IPO for its men’s health offshoot

Damian Garde Ampio Pharmaceuticals has postponed a plot to spin out one of its subsidiaries through an IPO, citing unfavorable market conditions. FierceBiotech News

FDA adds PML death scenario to Tecfidera label

Eric Palmer When Biogen Idec reported last month that a patient taking its hot multiple sclerosis pill Tecfidera had developed a rare brain infection and died, the drugmaker said it ...

Belgium’s Promethera banks $31M for orphan disease R&D

Damian Garde Promethera Biosciences has put together €25.3 million ($ 31.4 million) in equity and loans to hit the gas on its stem cell treatment for rare liver diseases. FierceBiotech ...

Bayer may hive off another unit as it doubles down on pharma, consumer health

Carly Helfand Turns out it may not be just Bayer's plastics business that's on its way out the door. The company is reportedly exploring a sale of its diabetes device business ...

GSK shareholders to vote on Novartis megadeal in December

Carly Helfand Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline and Novartis worth more than $ 20 billion. FiercePharma News

Report: Woodford is diving full on into biotech with new $314M fund

Damian Garde High profile U.K. investor Neil Woodford made headlines last week when he invested $ 25 million into Northwest Biotherapeutics, and that's a sign of much more to come, ...

EMA, like FDA, says testosterone-raising drugs are not for lifestyle use

Eric Palmer The European Medicines Agency has thrown more cold water on sales of testosterone-raising meds as a party drug for aging men. The agency said today that the evidence is ...

AstraZeneca earmarks $200M to support its burgeoning biologics pipeline

Damian Garde Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $ 200 million to build ...
Page 1 of 1012345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS